Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.78
-5.09 (-3.61%)
Streaming Delayed Price
Updated: 3:37 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
54
55
Next >
3 Consumer Goods Stocks That Will Define the Next Decade
November 21, 2023
These companies can be expected to continue shaping our lives for the foreseeable future thanks to their strong brands.
Via
InvestorPlace
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
November 21, 2023
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,...
Via
Benzinga
Topics
ETFs
Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.
November 21, 2023
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
Via
Chartmill
This Is What Whales Are Betting On Novo Nordisk
November 20, 2023
Via
Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Technical Analysis observations.
November 20, 2023
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Via
Chartmill
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
November 20, 2023
New medicines for weight loss and diabetes stand to disrupt the competitive scene.
Via
The Motley Fool
Better Growth Stock: Novo Nordisk vs. Eli Lilly
November 16, 2023
These companies have been attracting plenty of attention lately.
Via
The Motley Fool
Better Growth Stock: Pfizer vs. Novo Nordisk
November 14, 2023
One is growing now, and the other will grow soon.
Via
The Motley Fool
3 Stock-Split Stocks Billionaires Are Buying Hand Over Fist
November 20, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three industry-leading stocks that billionaire investors can't stop buying.
Via
The Motley Fool
Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?
November 19, 2023
Eli Lilly just received FDA approval for its obesity medication Zepbound, the sister treatment to its blockbuster drug Mounjaro.
Via
The Motley Fool
Exposures
Product Safety
GE, Amazon Lead 5 Stocks Near Buy Points With This Bullish Trait
November 18, 2023
Relative strength is key when choosing top stocks. GE, Amazon meet RS Line Blue Dot screen.
Via
Investor's Business Daily
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
November 17, 2023
It might have a hard time finding a home in the market.
Via
The Motley Fool
7 A-Rated Retirement Stocks for Your November Buy List
November 17, 2023
These A-rated retirement stocks represent companies that are stable, reliable, and well-suited for long-term investors.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
What's Going On With Novo Nordisk Stock Today?
November 13, 2023
On Saturday, Novo Nordisk A/S (NYSE: NVO) releas
Via
Benzinga
Big Players' Recent Trades in NVO Options
November 13, 2023
Via
Benzinga
Pharmaceutical Giant Eli Lilly Plans Expansion In Germany, Eyes Diabetes Drug Production: Report
November 16, 2023
Eli Lilly And Co (NYSE: LLY) reportedly intends to construct a production plant in western Germany with an estimated investment of €2 billion ($2.17 billion), marking an inaugural substantial...
Via
Benzinga
Why Eli Lilly Stock Flopped While the Market Popped Today
November 15, 2023
The company is apparently gearing up to spend at least $1 billion on a production facility in Europe.
Via
The Motley Fool
Ozempic Shortage Crisis - Germany Weighs Export Restrictions on Novo Nordisk's Drug
November 15, 2023
Germany's Federal Institute for Drugs and Medical Devices (BfArM) is reportedly contemplating a potential export prohibition on Novo Nordisk A/S's (NYSE: NVO) popular diabetes medication, Ozempic,
Via
Benzinga
Good technical signals and a possible breakout for NOVO-NORDISK A/S-SPONS ADR.
November 15, 2023
A technical analysis of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) shows it may be setting up for a breakout.
Via
Chartmill
Novo Nordisk's Ozempic Usage Suspended - Belgium Implements Temporary Ban Amid Medication Shortage
November 14, 2023
Belgium has temporarily banned Novo Nordisk A/S's (NYSE: NVO) Ozempic for weight
Via
Benzinga
Wegovy's Sales Potential Could Go Far Beyond Just Weight-Loss Treatment
November 14, 2023
Investors will pay a premium for Novo Nordisk's stock as it has a phenomenal drug in its portfolio.
Via
The Motley Fool
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
November 14, 2023
A red-hot product or service right now doesn't mean much if demand for it isn't going to last.
Via
The Motley Fool
Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning
November 14, 2023
It's already taking actions to shore up its future position.
Via
The Motley Fool
3 Safe Stocks to Buy for Solid Returns
November 14, 2023
For investors who seek to keep their returns stable during uncertain times, these safe stocks could be beneficial to their portfolios.
Via
InvestorPlace
What Are Pfizer's Prospects In Obesity Pill Market? Analysts Say Optimism, Cautiousness Surround With Data Awaited Next Year
November 13, 2023
Pfizer Inc (NYSE: PFE) is turning its focus to the weight loss drug market, aiming to capture a $10 billion segment with its experimental obesity
Via
Benzinga
Is There Room for Improvement In Weight Loss Arena? Analysts Evaluate Novo Nordisk Data, Emphasize Opportunities for Eli Lilly
November 13, 2023
Eli Lilly And Co's (NYSE: LLY) investigational RNA-directed drug lepodisiran lowered lipoprotein(a) levels in a Phase 1 study. Elevated levels of Lp(a) have been associated with a higher risk of heart...
Via
Benzinga
Novo Nordisk, Eli Lilly Skid — But These Weight-Loss Results Are 'Hard To Ignore'
November 13, 2023
Patients who took Wegovy for five years had a 70% reduced risk of developing diabetes.
Via
Investor's Business Daily
The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight’
November 13, 2023
Investors curious to identify the next magnificent 7 stock should start here as the clues are fairly straightforward.
Via
InvestorPlace
Better Buy Now: Novo Nordisk vs. Eli Lilly
November 13, 2023
Both of these companies are reporting positive news for their competing weight-loss drugs, but which is the better stock to buy now?
Via
The Motley Fool
Wegovy Weight Loss Drug Cuts Heart Complication Risk, Says Trial
November 11, 2023
A clinical trial has revealed that Novo Nordisk's (NYSE: NVO) weight loss drug Wegovy significantly decreases the risk of serious heart complications.
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.